Article Type
Changed
Wed, 07/07/2021 - 10:42

Key clinical point: Addition of dexamethasone significantly reduced the incidence of post-embolization syndrome in HCC patients after transarterial chemoembolization.

Major finding: The incidence of post-embolization events after TACE included abdominal pain in 55.6% in patients who underwent TACE plus lipiodol and chemotherapeutic emulsion vs. 36.1% in those who also received dexamethasone. Rates of fever, nausea, vomiting, and incidence of infection also were significantly lower in the dexamethasone patients compared to standard TACE patients.

Study details: The data come from a retrospective study of 255 HCC patients who underwent transarterial chemoembolization (TACE); patients were divided into two groups nonrandomly to receive TACE using lipiodol + chemotherapeutic emulsion group (133 patients) or TACE using lipiodol + dexamethasone + chemotherapeutic emulsion group (122 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Lu H et al. BMC Gastroenterol. 2021 Jun 11. doi: 10.1186/s12876-021-01839-w.

Publications
Topics
Sections

Key clinical point: Addition of dexamethasone significantly reduced the incidence of post-embolization syndrome in HCC patients after transarterial chemoembolization.

Major finding: The incidence of post-embolization events after TACE included abdominal pain in 55.6% in patients who underwent TACE plus lipiodol and chemotherapeutic emulsion vs. 36.1% in those who also received dexamethasone. Rates of fever, nausea, vomiting, and incidence of infection also were significantly lower in the dexamethasone patients compared to standard TACE patients.

Study details: The data come from a retrospective study of 255 HCC patients who underwent transarterial chemoembolization (TACE); patients were divided into two groups nonrandomly to receive TACE using lipiodol + chemotherapeutic emulsion group (133 patients) or TACE using lipiodol + dexamethasone + chemotherapeutic emulsion group (122 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Lu H et al. BMC Gastroenterol. 2021 Jun 11. doi: 10.1186/s12876-021-01839-w.

Key clinical point: Addition of dexamethasone significantly reduced the incidence of post-embolization syndrome in HCC patients after transarterial chemoembolization.

Major finding: The incidence of post-embolization events after TACE included abdominal pain in 55.6% in patients who underwent TACE plus lipiodol and chemotherapeutic emulsion vs. 36.1% in those who also received dexamethasone. Rates of fever, nausea, vomiting, and incidence of infection also were significantly lower in the dexamethasone patients compared to standard TACE patients.

Study details: The data come from a retrospective study of 255 HCC patients who underwent transarterial chemoembolization (TACE); patients were divided into two groups nonrandomly to receive TACE using lipiodol + chemotherapeutic emulsion group (133 patients) or TACE using lipiodol + dexamethasone + chemotherapeutic emulsion group (122 patients).

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Lu H et al. BMC Gastroenterol. 2021 Jun 11. doi: 10.1186/s12876-021-01839-w.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: HCC July 2021
Gate On Date
Mon, 06/07/2021 - 10:30
Un-Gate On Date
Mon, 06/07/2021 - 10:30
Use ProPublica
CFC Schedule Remove Status
Mon, 06/07/2021 - 10:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article